Patents by Inventor Wendell Wilkie Wilkerson

Wendell Wilkie Wilkerson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5990132
    Abstract: Compounds of Formula (I) have been shown to enhance the release of the neurotransmitter acetylcholine, and thus may be useful in the treatment of diseases of man where subnormal levels of this neurochemical are found, such as in Alzheimer's disease, and other conditions involving learning and cognition.
    Type: Grant
    Filed: June 17, 1996
    Date of Patent: November 23, 1999
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Christopher Allan Teleha, Wendell Wilkie Wilkerson, Richard Alan Earl
  • Patent number: 5750528
    Abstract: Compounds which block neuronal M-channels are useful for treating conditions involving neurotransmitter deficiencies, traumatic brain injury, or the depressive phase of bipolar disorder. Compounds can be evaluated for utility in treating these conditions by determining whether they are capable of blocking neuronal M-channels.
    Type: Grant
    Filed: February 1, 1995
    Date of Patent: May 12, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Barry Stephen Brown, Simon Piers Aiken, Robert Zaczek, Paul Richard Hartig, Christopher Allan Teleha, Wendell Wilkie Wilkerson, Richard Alan Earl
  • Patent number: 5698559
    Abstract: Compounds of Formula I have been shown to enhance the release of the neurotransmitter acetylcholine, and thus may be useful in the treatment of diseases of man, such as in Alzheimer's disease and other conditions involving learning and cognition, where subnormal levels of this neurochemical are found.The compounds of this invention can be described as shown in Formula I ##STR1## where Q is ##STR2## R.sup.1 is 4-, 3-, or 2-pyridyl, pyrimidyl, pyrazinyl, or fluoro-4-pyridyl;R.sup.2 and R.sup.3 are independently H, F, Cl, Br, NO.sub.2, OH, --R.sup.4, --O--R.sup.4, --CO.sub.2 R.sup.4, --COR.sup.4, --CONH.sub.2, --CONHR.sup.4, --CONR.sub.4 R.sup.4', --S(O).sub.m2 --R.sup.4, NH.sub.2, CF.sub.3, NHR.sup.4, NR.sup.4 R.sup.4' ;R.sup.4 and R.sup.4' are independently H, alkyl of 1 to 4 carbons, CH.sub.2 Phe-W or Phe-W;Phe is a phenyl group;R.sup.5 is --(CH.sub.2).sub.n --Y or --OCOR.sup.4 ;Y is H, OH, NH.sub.2, NHR.sup.4, NR.sup.4 R.sup.4', NHCOR.sup.4, NHCO.sub.2 R.sup.4, NHS(O).sub.2 R.sup.4 ; F, Cl, Br, OR.sup.
    Type: Grant
    Filed: March 25, 1996
    Date of Patent: December 16, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Wendell Wilkie Wilkerson, Christopher Allan Teleha